ImmuPharma's lupus drug enters Ph II
London, UK-headquartered drug discovery company ImmuPharma says that its developmental lupus treatment, IPP-201101, has entered Phase II assessment. This follows the successful completion of a Phase I trial in May of this year that established the compound's safety, pharmacokinetics and tolerability profile.
The Phase II trial will be a proof-of-concept study, designed to establish the most effective dose of the drug in addition to further establishing its safety and efficacy. The compound's effect will be assessed via measurement of disease-related biomarkers. The firm added that its expects to complete the program and publish results by the end of the year.
Richard Warr, ImmuPharma's executive chairman, said: "we believe IPP-201101 has blockbuster potential." He added that the low marketing costs and the low cost of goods make the drug an ideal candidate for licensing deals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze